Commodore Capital Portfolio holdings
Commodore Capital runs funds that back drug developers, from early-stage public companies to late-stage private ones. It aims to fill a gap it sees between traditional venture capital and public market funds. Its thesis is that small biopharma companies, not large drugmakers, drive much of the innovation in areas like genetic medicines and cell therapies. Michael Kramarz and Egen Atkinson, both medical doctors with MBAs, are its managing partners. They indirectly own a majority of the firm, which began operating in 2019. The funds are open to institutions, pension plans, endowments and high net worth individuals.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
C4 Therapeutics
CCCC
|
+$14M |
| 2 |
TRIL
Trillium Therapeutics
TRIL
|
+$12.3M |
| 3 |
Cymabay Therapeutics
CBAY
|
+$11.2M |
| 4 |
CNST
Constellation Pharmaceuticals
CNST
|
+$10.7M |
| 5 |
Kronos Bio
KRON
|
+$9.38M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.36% |
| 2 | Financials | 1.51% |
| 3 | Industrials | 1.12% |
Similar funds
Commodore Capital's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Commodore Capital, which disclosed 28 positions worth $184M. Its ten largest holdings account for 55% of the portfolio.
Its largest position is C4 Therapeutics: 481,094 shares worth $15.9M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, followed by Financials and Industrials.
- Commodore Capital's largest Q4 2020 buy was C4 Therapeutics: 481,094 shares worth $15.9M.
- Commodore Capital's ten largest holdings make up 55% of its $184M portfolio in Q4 2020.
- Commodore Capital disclosed 28 positions in Q4 2020, its first 13F filing on record.
Based on Commodore Capital's 13F filing for Q4 2020, filed 16 Feb 2021.